Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Atsuyoshi Seki"'
Autor:
Sae Yumita, Sadahisa Ogasawara, Miyuki Nakagawa, Susumu Maruta, Tomomi Okubo, Norio Itokawa, Yotaro Iino, Masamichi Obu, Yuki Haga, Atsuyoshi Seki, Tadayoshi Kogure, Takamasa Ishino, Keita Ogawa, Kisako Fujiwara, Terunao Iwanaga, Naoto Fujita, Takafumi Sakuma, Ryuta Kojima, Hiroaki Kanzaki, Keisuke Koroki, Masanori Inoue, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Takayuki Kondo, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Ei Itobayashi, Masanori Atsukawa, Yoshihiro Koma, Ryosaku Azemoto, Kenji Ito, Hideaki Mizumoto, Jun Kato, Naoya Kato
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Hyperprogressive disease (HPD) is a phenomenon with greatly accelerated tumor growth and clinical deterioration rates compared to pre-therapy, in patients treated with immune checkpoint inhibitors (ICI). The aim of this study is t
Externí odkaz:
https://doaj.org/article/e6438030eab2449d8f1c4414595c6e53
Autor:
Keisuke Koroki, Naoya Kanogawa, Susumu Maruta, Sadahisa Ogasawara, Yotaro Iino, Masamichi Obu, Tomomi Okubo, Norio Itokawa, Takahiro Maeda, Masanori Inoue, Yuki Haga, Atsuyoshi Seki, Shinichiro Okabe, Yoshihiro Koma, Ryosaku Azemoto, Masanori Atsukawa, Ei Itobayashi, Kenji Ito, Nobuyuki Sugiura, Hideaki Mizumoto, Hidemi Unozawa, Terunao Iwanaga, Takafumi Sakuma, Naoto Fujita, Hiroaki Kanzaki, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Tomoko Saito, Takayuki Kondo, Eiichiro Suzuki, Yoshihiko Ooka, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Tatsuo Kanda, Hitoshi Maruyama, Jun Kato, Naoya Kato
Publikováno v:
Liver Cancer, Pp 1-12 (2021)
Background: There is no standard posttreatment for patients with advanced hepatocellular carcinoma (HCC) in whom lenvatinib therapy has failed. This study aimed to investigate rates of migration to posttreatment after lenvatinib and to explore candid
Externí odkaz:
https://doaj.org/article/4cc7f3182bb149d4bf42ff53cc56445b
Autor:
Susumu Maruta, Sadahisa Ogasawara, Yoshihiko Ooka, Masamichi Obu, Masanori Inoue, Norio Itokawa, Yuki Haga, Atsuyoshi Seki, Shinichiro Okabe, Ryosaku Azemoto, Ei Itobayashi, Masanori Atsukawa, Nobuyuki Sugiura, Hideaki Mizumoto, Keisuke Koroki, Kengo Kanayama, Hiroaki Kanzaki, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Takayuki Kondo, Eiichiro Suzuki, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Tatsuo Kanda, Hitoshi Maruyama, Naoya Kato
Publikováno v:
Liver Cancer, Pp 1-15 (2020)
Background: The present study aimed to assess the efficacy and safety of lenvatinib and verify the possibility of lenvatinib for the expanded indication from the REFLECT trial in patients with advanced hepatocellular carcinoma (HCC) in real-world pra
Externí odkaz:
https://doaj.org/article/20c3dbbd10674550aaa6a8bc4f4b0e9a
Autor:
Miyuki Nakagawa, Masanori Inoue, Sadahisa Ogasawara, Susumu Maruta, Tomomi Okubo, Norio Itokawa, Yotaro Iino, Masamichi Obu, Yuki Haga, Atsuyoshi Seki, Yasuharu Kikuchi, Tadayoshi Kogure, Sae Yumita, Takamasa Ishino, Keita Ogawa, Kisako Fujiwara, Terunao Iwanaga, Naoto Fujita, Takafumi Sakuma, Ryuta Kojima, Hiroaki Kanzaki, Keisuke Koroki, Takashi Taida, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Takayuki Kondo, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Ei Itobayashi, Masanori Atsukawa, Yoshihiro Koma, Ryosaku Azemoto, Kenji Ito, Hideaki Mizumoto, Masami Shinozaki, Jun Kato, Naoya Kato
Publikováno v:
Cancer. 129:590-599
Although the efficacy of atezolizumab has been demonstrated in randomized controlled trials, its long-term efficacy and association with adverse events in real-world practice are unknown. This study was designed to shed light on these issues.In this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b54ec0aa54455ab40bab1036ea7a7b81
https://doi.org/10.1002/cncr.34559
https://doi.org/10.1002/cncr.34559
Autor:
Atsushi Iwama, Hiromitsu Nakauchi, Hideki Taniguchi, Osamu Yokosuka, Yutaka Yonemitsu, Yohei Morita, Atsuyoshi Seki, Ryutaro Aoki, Atsunori Saraya, Satoru Miyagi, Tetsuhiro Chiba
Supplementary Figure 2 from The Polycomb Gene Product BMI1 Contributes to the Maintenance of Tumor-Initiating Side Population Cells in Hepatocellular Carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0e4422bd865c7efa06b726acbc7427e
https://doi.org/10.1158/0008-5472.22375242.v1
https://doi.org/10.1158/0008-5472.22375242.v1
Autor:
Atsushi Iwama, Hiromitsu Nakauchi, Hideki Taniguchi, Osamu Yokosuka, Yutaka Yonemitsu, Yohei Morita, Atsuyoshi Seki, Ryutaro Aoki, Atsunori Saraya, Satoru Miyagi, Tetsuhiro Chiba
Side population (SP) cell analysis and sorting have been successfully applied to hepatocellular carcinoma (HCC) cell lines to identify a minor cell population with cancer stem cell properties. However, the molecular mechanisms operating in SP cells r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15cdebd85f90e77442a1b3750952d781
https://doi.org/10.1158/0008-5472.c.6497748.v1
https://doi.org/10.1158/0008-5472.c.6497748.v1
Autor:
Atsushi Iwama, Hiromitsu Nakauchi, Hideki Taniguchi, Osamu Yokosuka, Yutaka Yonemitsu, Yohei Morita, Atsuyoshi Seki, Ryutaro Aoki, Atsunori Saraya, Satoru Miyagi, Tetsuhiro Chiba
Supplementary Figure Legends 1-3 from The Polycomb Gene Product BMI1 Contributes to the Maintenance of Tumor-Initiating Side Population Cells in Hepatocellular Carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3221c604a836463071820d3ce18ef0b
https://doi.org/10.1158/0008-5472.22375236
https://doi.org/10.1158/0008-5472.22375236
Autor:
Atsushi Iwama, Hiromitsu Nakauchi, Hideki Taniguchi, Osamu Yokosuka, Yutaka Yonemitsu, Yohei Morita, Atsuyoshi Seki, Ryutaro Aoki, Atsunori Saraya, Satoru Miyagi, Tetsuhiro Chiba
Supplementary Figure 3 from The Polycomb Gene Product BMI1 Contributes to the Maintenance of Tumor-Initiating Side Population Cells in Hepatocellular Carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62b82d3322535b98e6b9462003777a83
https://doi.org/10.1158/0008-5472.22375239
https://doi.org/10.1158/0008-5472.22375239
Autor:
Atsushi Iwama, Hiromitsu Nakauchi, Hideki Taniguchi, Osamu Yokosuka, Yutaka Yonemitsu, Yohei Morita, Atsuyoshi Seki, Ryutaro Aoki, Atsunori Saraya, Satoru Miyagi, Tetsuhiro Chiba
Supplementary Figure 1 from The Polycomb Gene Product BMI1 Contributes to the Maintenance of Tumor-Initiating Side Population Cells in Hepatocellular Carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b303ff9826e6234247ef8ba8486f90f8
https://doi.org/10.1158/0008-5472.22375245.v1
https://doi.org/10.1158/0008-5472.22375245.v1
Autor:
Sae Yumita, Sadahisa Ogasawara, Miyuki Nakagawa, Susumu Maruta, Tomomi Okubo, Norio Itokawa, Yotaro Iino, Masamichi Obu, Yuki Haga, Atsuyoshi Seki, Tadayoshi Kogure, Takamasa Ishino, Keita Ogawa, Kisako Fujiwara, Terunao Iwanaga, Naoto Fujita, Takafumi Sakuma, Ryuta Kojima, Hiroaki Kanzaki, Keisuke Koroki, Masanori Inoue, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Takayuki Kondo, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Ei Itobayashi, Masanori Atsukawa, Yoshihiro Koma, Ryosaku Azemoto, Kenji Ito, Hideaki Mizumoto, Jun Kato, Naoya Kato
Background Hyperprogressive disease (HPD) is a phenomenon with greatly accelerated tumor growth and clinical deterioration rates compared to pre-therapy, in patients treated with immune checkpoint inhibitors (ICI). The aim of this study is to clarify
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e434e1b7ba9ca13f2088be76408cf9f8
https://doi.org/10.21203/rs.3.rs-1901579/v1
https://doi.org/10.21203/rs.3.rs-1901579/v1